SCHEMBL15865616

SCHEMBL15865616

COC(=O)c1cc(=O)cc(C(=O)OC)[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
NFKB1 P19838 2/20 0.54
ALOX15 P16050 1/20 0.54
BLM P54132 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GAA P10253 4/20 0.50
KDM4E B2RXH2 3/20 0.50
GLA P06280 2/20 0.50
MAPK1 P28482 1/20 0.47
XDH P47989 4/20 0.46
MAPT P10636 2/20 0.44
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
ULK1 O75385 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27041790 0.88 CYP1A2 (0.55) CYP1A2NFKB1ALOX15BLMSMN1; SMN2
SCHEMBL70624 0.78 GAA (0.67) CYP1A2GAAKDM4EGLAMAPK1
SCHEMBL118496 0.77 CYP1A2 (1.00) CYP1A2SMN1; SMN2GAAKDM4EGLA
SCHEMBL12867867 0.77 ALOX15 (0.48) CYP1A2NFKB1ALOX15BLMSMN1; SMN2
SCHEMBL28191570 0.77 CYP1A2 (0.47) CYP1A2SMN1; SMN2GAAKDM4EGLA
SCHEMBL6802319 0.74 CYP1A2 (0.53) CYP1A2NFKB1GAAKDM4EGLA
SCHEMBL2710412 0.74 CYP1A2 (0.62) CYP1A2SMN1; SMN2GAAKDM4EGLA
SCHEMBL17362895 0.74 CYP1A2 (0.62) CYP1A2GAAKDM4EGLAMAPK1
SCHEMBL12872719 0.74 CYP1A2 (0.68) CYP1A2SMN1; SMN2GAAKDM4EGLA
SCHEMBL29849942 0.74 CYP1A2 (0.62) CYP1A2SMN1; SMN2GAAKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023073181-A2 METHODS FOR NUCLEIC ACID CLEAVAGE CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-05-04 WO disclosed
EP-2536691-B1 BIFUNCTIONAL CHELATING AGENTS Nordion (Canada) Inc (CA) 2017-11-22 EP disclosed
US-8772446-B2 Bifunctional chelating agents NORDION (CANADA) INC. (CA) 2014-07-08 US disclosed
US-8772446-B2 Bifunctional chelating agents NORDION (CANADA) INC. (CA) 2014-07-08 US disclosed
US-20110313130-A1 BIFUNCTIONAL CHELATING AGENTS NORDION (CANADA) INC. 2011-12-22 US disclosed
US-20110313130-A1 BIFUNCTIONAL CHELATING AGENTS NORDION (CANADA) INC. 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313130-A1 BIFUNCTIONAL CHELATING AGENTS FCGRT, C1QBP, H1-2 CYP1A2 2997/4885NFKB1 1512/4885ALOX15 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.